This filing is a routine employee communication with no new deal terms or financial guidance. The Q1 revenue growth is strong but already disclosed. Monitor the definitive proxy statement for shareholder vote details and any potential competing bids. The stock will likely trade on the acquisition spread until closing.
CPRX drugs
CPRX drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · May 12 $31.14entry
- T+1 · 6mo ago +0.06%α −0.51% · $31.16
- T+5 · 6mo ago +0.29%α +0.21% · $31.23
- T+20 · 5mo ago +0.64%α +2.37% · $31.34
- T+60 · due 3mo ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Catalyst Pharmaceuticals filed additional definitive proxy soliciting materials (DEFA14A) containing an employee update email from the CEO regarding the pending acquisition by Angelini Pharma. The email confirms Q1 2026 revenues of $149.4 million (28.2% YoY growth) and reiterates the expected closing in Q3 2026. This is a routine communication to employees and does not contain new material information for shareholders beyond what was previously disclosed.
Key Financial Metrics
Key Facts
- Filing is a DEFA14A containing an employee email from Catalyst CEO regarding the Angelini Pharma acquisition.
- Q1 2026 revenues were $149.4 million, representing 28.2% year-over-year growth, including $135.6 million from FIRDAPSE and AGAMREE.
- Transaction expected to close in Q3 2026; integration planning underway.
- Catalyst will enter a quiet period, continuing quarterly earnings reports but suspending investor calls and conferences.
- Town hall scheduled for May 27, 2026 with Angelini Pharma CEO.
Financial Impact
Q1 2026 revenues of $149.4 million, up 28.2% YoY; no new financial guidance or deal terms provided.
Risk Factors
- Transaction may not close if stockholder approval is not obtained or regulatory conditions are not satisfied.
- Integration risks post-closing could affect combined entity performance.
- Quiet period limits management communication, increasing uncertainty for investors.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-218309 |
| Document: 0001193125-26-218309-index-headers.html | 0001193125-26-218309 |
| Document: 0001193125-26-218309-index.html | 0001193125-26-218309 |
| Document: 0001193125-26-218309.txt | 0001193125-26-218309 |
Track record
16 reports on CPRX
4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +25.72% at T+60 after the Feb 25, 2026 report. 6 of 9 went positive at some point.
Filters
- Nov 4, 202612d ago Institutional Cluster Bearish 4/10 No price data
- Aug 22, 202612w ago Institutional Cluster Mixed 5/10 No price data
- Jul 24, 202616w ago 15-12G Bearish 9/10 Entry $31.49 No price data
- Jul 17, 202617w ago EFFECT Bearish 5/10 Entry $31.49 No price data
- Jul 15, 202617w ago 25-NSE Bearish 9/10 Entry $31.49 No price data
- Jul 8, 202618w ago 8-K Bullish 6/10 Entry $31.47 No price data
- Jun 30, 202619w ago DEFA14A Neutral 3/10 Entry $31.44 No price data
- Jun 30, 202619w ago 8-K Neutral 4/10 Entry $31.44 No price data
- May 28, 202624w ago PREM14A Bullish 8/10 Entry $31.23 to $31.46 ▲ +0.74% +2.53% vs SPY
- May 12, 202626w ago DEFA14A Neutral 3/10 Viewing Entry $31.14 to $31.34 ▲ +0.64% +2.37% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers